london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Aflibercept in AMD resistant to intensive ranibizumab treatment

Poster Details

First Author: S.Abou-Ltaif UK

Co Author(s):    E. Thompson   N. Karia               0   0 0   0 0   0 0   0 0

Abstract Details


To investigate the effect of aflibercept 2.0 mg in patients treated with more than 7 consecutive injections of ranibizumab 0.5 mg with persistent fluid on OCT.


Eye unit, Southend University hospital


prospective case-series study at the eye unit of Southend University hospital in exudative AMD cases with persistent fluid on regular ranibizumab 0.5 mg treatment switched to intravitreal aflibercept 2.0 mg treatment and followed for 6 months. Details of number of previous injections, best corrected visual acuity, central subfoveal thickness before and after aflibercept injection using spectral domain OCT are collected at every visit.


A total of 20 eyes of 19 patients with exudative AMD with persistent fluid after an average of 14 regular ranibizumab injections (range of 7-26) were switched to aflibercept during the study period. At 3 month, 100% of patients showed anatomic improvement and 100% were dry after a single aflibercept injection. Most of patients remained dry at 6 months with no further treatment.


Even at a stage where a permanent damage to the macula is seen, Aflibercept was able to dry the macula. Visual acuity in these patients understandably did not improve but in few cases. We recommend to have a low threshold for switching to Aflibercept when no response is seen after 3 consecutive injections to avoid the stage of permanent macular damage.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy